This article was originally published in The Gray Sheet
Firm no longer co-markets Hyalgan osteoarthritis treatment, as was reported in "The Gray Sheet" (July 9, 2001, p. 9); the arrangement expired at the end of 2000 (1"The Gray Sheet" Feb. 5, 2001, p. 4)
You may also be interested in...
Smith & Nephew's 400-rep sales force plans to emphasize the extensive clinical experience behind the firm's Supartz hyaluronic acid-based injectable treatment for osteoarthritis of the knee in marketing the product to orthopedic surgeons.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.